Authors: Grimm, RH Margolis, KL Papademetriou, V Cushman, WC Ford, CE Bettencourt, J Alderman, MH Basile, JN Black, HR DeQuattro, V Eckfeldt, J Hawkins, CM Perry, HM Proschan, M

Citation: Rh. Grimm et al., Baseline characteristics of participants in the Antihypertensive and LipidLowering Treatment to Prevent Heart Attack Trial (ALLHAT), HYPERTENSIO, 37(1), 2001, pp. 19-27

Authors: Probstfield, JL Applegate, WB Berge, KE Cutler, JA Davis, B Furberg, CD Hawkins, CM Pressel, S Schron, EB Smith, WM

Citation: Jl. Probstfield et al., Systolic Hypertension in the Elderly Program (SHEP): The first demonstration that lowering systolic hypertension reduced total stroke and all coronary heart disease, CLINICAL TRIALS IN HYPERTENSION, 2001, pp. 195-231

Authors: Sacks, FM Tonkin, AM Shepherd, J Braunwald, E Cobbe, S Hawkins, CM Keech, A Packard, C Simes, J Byington, R Furberg, CD

Citation: Fm. Sacks et al., Effect of pravastatin on coronary disease events in subgroups defined by coronary risk factors - The prospective pravastatin pooling project, CIRCULATION, 102(16), 2000, pp. 1893-1900

Authors: Sacks, FM Pfeffer, MA Moye, LA Hawkins, CM Davis, BR Rouleau, JL Cole, TG Braunwald, E

Citation: Fm. Sacks et al., Cholesterol and recurrent events trial (CARE) - The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels, CHOLESTEROL-LOWERING THERAPY, 2000, pp. 63-89